Home / Evidence ledger / Retatrutide
~39 amino acids · GLP-1 / GIP / glucagon triple agonist
Not approvedThe strongest trial data of anything on this page, and simultaneously one of the riskiest things to obtain outside a trial. It is investigational, not approved anywhere, and independent testing of grey-market samples has been poor.
Free, no obligation
Every inquiry gets a real answer from a person. If what you're asking about isn't supported by evidence, we'll say so.
Schematic structure, not to scale. Beads represent amino acid residues along the backbone.
In theory, retatrutide is designed to do three things at once: suppress appetite through GLP-1, sharpen insulin response through GIP, and raise energy expenditure through glucagon. Unlike almost everything else on this site, that theory has been tested properly: roughly 28% mean weight loss at 80 weeks in a Phase 3 programme. The result is real. It belongs to a drug you cannot legally obtain, made under conditions the grey market does not replicate.
The detail, if you want it
An investigational triple receptor agonist developed by Eli Lilly, acting at the GLP-1, GIP and glucagon receptors. The addition of glucagon receptor activity is what distinguishes it from tirzepatide, and is thought to contribute to energy expenditure alongside appetite suppression.
The trial evidence above applies to Lilly's drug, manufactured under cGMP, at verified dose, in a monitored population. It does not transfer to material bought online. Independent analysis has been notably poor for this compound specifically, 37 grey-market retatrutide samples received failing grades from Janoshik Analytical. Lilly has also been actively litigating against suppliers. A compound performing well in Phase 3 says nothing about the contents of an unverified vial bearing the same name.
That is the question a consultation answers. A licensed physician reviews your situation and tells you what the evidence supports. Including when the honest answer is no.
See consultationsAlso on the ledger